"The financial structure of the acquisition includes a guaranteed purchase price of $55 million, paid over five years, with an initial payment of $10 million at closing."
"The remaining $95 million is contingent on future performance milestones, meaning the headline $150 million figure represents the ceiling if Bioniq hits every target post-integration."
"Bioniq's core proposition is that generic multivitamins are an inefficient substitute for supplements calibrated to what an individual's blood actually shows."
"The platform ingests blood biomarker results alongside a health questionnaire and generates a personalised daily formula, with over six million biomarker data points collected across five continents."
Herbalife has announced the acquisition of Bioniq, a London-based startup specializing in personalized supplements based on blood biomarker data. The deal is valued at up to $150 million, with a guaranteed payment of $55 million over five years. The remaining $95 million is contingent on Bioniq meeting future performance milestones. Founded in 2019, Bioniq aims to provide tailored supplement regimens, utilizing over six million biomarker data points to create individualized formulas, addressing the inefficiencies of generic multivitamins.
Read at TNW | Startups-Technology
Unable to calculate read time
Collection
[
|
...
]